Alison
Buckley
a,
James
Warren
a,
Rohanah
Hussain
b and
Rachel
Smith
*a
aToxicology Department, UK Health Security Agency, Harwell Science and Innovation Campus, Didcot, Oxfordshire OX11 0RQ, UK. E-mail: Rachel.smith@ukhsa.gov.uk
bDiamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, Oxfordshire OX11 0DE, UK
First published on 10th February 2023
Inhaled nanoparticles (NPs) depositing in the alveolar region of the lung interact initially with a surfactant layer and in vitro studies have demonstrated that NPs can adversely affect the biophysical function of model pulmonary surfactants (PS), of which surfactant protein B (SP-B) is a key component. Other studies have demonstrated the potential for NPs to modify the structure and function of proteins. It was therefore hypothesised that NPs may affect the biophysical function of PS by modifying the structure of SP-B. Synchrotron radiation circular dichroism (SRCD) spectroscopy was used to explore the effect of various concentrations of gold nanoparticles (AuNPs) (5, 10, 20 nm), silver nanoparticles (AgNPs) (10 nm) and silver citrate on the secondary structure of surfactant protein B analogue, SP-B1–25, in a TFE/PB dispersion. For Au and Ag NPs the SRCD spectra indicated a concentration dependent reduction in the α-helical structure of SP-B1–25 (5 nm AuNP ≈ 10 nm AgNP ≫ 10 nm AuNP > 20 nm AuNP). For AuNPs the effect was greater for the 5 nm size, which was not fully explained by consideration of surface area. The impact of the 10 nm AgNPs was greater than that of the 10 nm AuNPs and the effect of AgNPs was greater than that of silver citrate at equivalent Ag mass concentrations. For 10 nm AuNPs, SRCD spectra for dispersions in, the more physiologically relevant, DPPC showed a similar concentration dependent pattern. The results demonstrate the potential for inhaled NPs to modify SP-B1–25 structure and thus potentially adversely impact the physiological function of the lung, however, further studies are necessary to confirm this.
Pulmonary surfactant comprises a mixture of phospholipids (∼80%), neutral lipids (∼10%) and proteins (∼10%).6 The most abundant component (∼40%) is the phospholipid 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (dipalmitolphosphatidylcholine, DPPC), which is a zwitterionic surfactant. To date four surfactant proteins (SPs) have been identified: SP-A, SP-B, SP-C and SP-D. Their functions are interrelated but primarily SP-A (∼5–6%) and SP-D (∼0.5%) play an important role in host immune defence (opsonins) and SP-B and SP-C in the biophysical functions of surfactant. SP-B and SP-C are small hydrophobic polypeptides each comprising around 1.0–1.5% of surfactant.7 Optimised surfactant behaviour requires: (a) the effective transfer of the surfactant from the alveolar type II cells, where it is produced, through the aqueous phase to the interface, followed by interfacial adsorption of the active molecules to form the surface film; (b) surface tension reduction to values close to 0 mN m−1 during the compression of the respiratory surface at expiration; and, (c) efficient re-spreading of the surface film during expansion at inspiration. The phospholipids play a key role (e.g. DPPC can achieve surface tension values close to 0 mN m−1 on compression) but in vitro studies have indicated that the presence of the surfactant proteins is required to optimise the surfactant layer function, with proteins involved in promoting adsorption, stabilisation and re-spreading whilst lipids are essentially responsible for the significant surface tension reduction during compression.8 In particular, SP-B, the only surfactant protein essential for life, is postulated to play key roles in interfacial adsorption and in the modification of lipid layer arrangements required for the conversion from mono- to multi- layers during respiration (“reservoir” formation).7,9
Langmuir–Wilhelmy Balance systems, pulsating bubble surfactometers, captive bubble tensiometers and constrained drop surfactometry, are frequently used to investigate surfactant function. Such methods monitor surface pressure during changes in surfactant monolayer area designed to mimic surface area changes in the lung during respiration and have been used widely to explore the impact of inhaled particles, including NPs, on lung surfactant model layers.10 For example, the results of studies using DPPC as a model surfactant have varied with some indicating no or minimal effects of NPs on surface tension behaviour,11 whilst others provide clear indications of negative changes to surface pressure-area isotherms.12–16 Similar experiments have also been undertaken using more complete models of pulmonary surfactant for a limited range of nanomaterials and found a deterioration in surface tension behaviour.17–20 For example, using the oscillating bubble technique, the effect of bare and coated polymeric NPs on the surface tension behaviour of a phospholipid mixture with and without the addition of different concentrations of SP-B and SP-C, alone and in combination, was investigated.21 The study found that SP-C supplemented phospholipid mixtures were more susceptible to biophysical inactivation by bare NP than phospholipid mixtures supplemented with SP-B and that effects were reduced for coated particles. They hypothesised that overall surfactant function was hindered due to a significant depletion of the SP content upon contact with the bare NPs and undertook incubation studies of the NPs with the surfactant which indicated a loss of SPs from the surfactant consistent with the biophysical effects seen.
The results of these in vitro studies indicate that NPs have the potential to inhibit the function of surfactant films and that in more physiological relevant surfactant models these effects may be mediated by interactions of NPs with SPs.11,18,21,22 Typical hypotheses in these cases relate to the impact of sequestration of surfactant, and in particular the protein components. These hypotheses either propose that SPs are present within the surfactant layer but bound to the NPs so that they are not able to perform their function, or that SPs bind to NPs which then leave the surfactant layer and are therefore removed from the system. Which of these mechanisms applies is considered dependent in a complex manner upon the physiochemical characteristics of the particles, including any coatings, in particular charge and hydrophobicity. For example, molecular dynamics modelling has indicated that model anionic hydrophilic NPs adsorb and pull SP-B1–25 out of a static surfactant monolayer.23 These ‘sequestration’ hypotheses are supported by other studies which indicate that proteins and lipids can bind to NPs (“corona” formation), and recent in vitro studies have confirmed that particles interacting with human lung lining fluid acquire a biomolecular corona containing SP-B.24,25
An alternative to ‘sequestration’ hypotheses for the effect of NPs on the function of surfactant films containing SPs is the hypothesis that NPs modify the secondary structure of SPs,26 which impacts on their behaviour (e.g. inactivates) within pulmonary surfactant and consequently affects surfactant film function. A number of studies, recently reviewed by Park (2020),27 have found that NPs can modify the structure of proteins, with many studies indicating the following typical conformational changes: α-helical component decreases and/or β-sheet formation increases – with effects influenced by a range of factors including the nanomaterial type (including coating, functionalization etc.), size, shape, charge and concentration.27 However, to date such studies have focussed on a limited range of proteins, in particular, bovine and human serum albumin, lysozyme and fibrinogen. The authors are not aware of any study on the effects of NPs on SP structure.
To address this gap, studies were undertaken of the effect of two types of NPs, gold (AuNP) and silver (AgNP), of a range of particle sizes and concentrations, on the secondary structure of a commonly used SP-B analogue, SP-B1–25.28 These NPs were chosen as they have been widely used in other studies. The majority of studies undertaken to explore the effects of NPs on the secondary structure of proteins have used circular dichroism (CD) spectroscopy,27,29 however, to measure protein concentrations in the micromolar and submicromolar range, the use of longer pathlength cuvette cells (5 to 10 cm) with small apertures required the use of a highly incident collimated microbeam that can be provided only at the Diamond Light Source B23 beamline for synchrotron radiation circular dichroism (SRCD). These measurements are not possible with bespoke bench-top CD spectropolarimeters. This approach was used successfully by Laera et al. (2011)30 to measure structural changes to a number of proteins exposed to NPs. Our study primarily used dispersions in Triflouroethanol (TFE), a commonly used solvent in CD studies, but DPPC was also used in some cases to represent a more physiologically realistic model.
Dispersions of Au and Ag NPs (a range of concentrations) and SP-B1–25, separately and in combination, were produced in Triflouroethanol (TFE) with 4 mM phosphate buffer (PB). To explore the effect of silver ions compared with the silver nanoparticles, silver citrate (Ag3C6H5O73−) was used (Sigma-Aldrich, USA) in place of the AgNPs in some samples. Silver citrate concentrations were chosen so that the silver concentration matched the range of AgNP concentrations used. While TFE has the advantage of ease of use and readily promotes the helical structure in SP-B1–25, it is not a physiologically relevant lung surfactant model. A preliminary investigation using DPPC (Sigma-Aldrich, USA), the main constituent of lung lining fluid, instead of TFE was therefore carried out with 10 nm AuNPs.
Preliminary optimisation experiments were undertaken, including, equipment calibration, sample cell choice and determination of optimum peptide/NP concentrations. For SP-B1–25 in TFE/PB, the best signal was achieved using a 5 cm path-length cell and a SP-B1–25 concentration of 4 μg ml−1 in TFE/4 mM phosphate buffer, 1:
4 v
:
v. For DPPC, the ideal lipid: SP-B1–25 ratio would be close to that in the lung (∼100
:
1, ref. 7). Using an SP-B1–25 concentration of 4 μg ml−1 though, the highest ratio achievable before absorbance became too great, was found to be 50
:
1. All DPPC samples were therefore made using 4 μg ml−1 SP-B1–25 in DPPC/4 mM PB, SP-B1–25:DPPC, 50
:
1 v
:
v. The maximum NP concentration which could be used varied for the different materials/sizes investigated, but in general, concentrations greater than 10 μg ml−1 caused too much absorption at lower wavelengths. NP concentrations were chosen so that comparison of equivalent mass concentrations, surface area concentrations and ratios of free to bound SP-B1–25 could be made across the different particle sizes and materials. Table 1 details all the concentrations used, alongside calculations of number concentration, surface area concentration and estimates of the ratio of free to bound SP-B1–25.
Sample | Nanoparticle concentration | Ratio free/bound (SP-B1–25) | Protein conformation | |||||
---|---|---|---|---|---|---|---|---|
Mass (μg ml−1) | Particle no. (# ml−1) | Surface area (nm2 ml−1) | α-Helix | β-Strand | Unordered | Turns | ||
a Equivalent Ag+ concentrations of 0.625 μg ml−1, 1.25 μg ml−1, 2.5 μg ml−1 and 4.451 μg ml−1 respectively. | ||||||||
SP-B only (I) | 0 | 0 | 0 | na | 24% | 25% | 29% | 22% |
SP-B only (II) | 0 | 0 | 0 | na | 25% | 25% | 28% | 22% |
SP-B only (with sodium citrate) | 0 | 0 | 0 | na | 28% | 23% | 25% | 23% |
5 nm AuNP | 0.625 | 4.93 × 1011 | 3.87 × 1013 | 27 | 21% | 30% | 27% | 22% |
1.25 | 9.85 × 1011 | 7.73 × 1013 | 13 | 14% | 36% | 27% | 23% | |
2.5 | 1.97 × 1012 | 1.55 × 1014 | 6 | 11% | 37% | 27% | 25% | |
5 | 3.94 × 1912 | 3.09 × 1014 | 2 | 12% | 38% | 26% | 23% | |
10 nm AuNP | 1.25 | 1.23 × 1011 | 3.87 × 1013 | 27 | 24% | 26% | 29% | 21% |
2.5 | 2.46 × 1011 | 7.73 × 1013 | 13 | 26% | 24% | 27% | 23% | |
5 | 4.93 × 1011 | 1.55 × 1014 | 6 | 18% | 30% | 29% | 23% | |
10 | 9.85 × 1011 | 3.09 × 1014 | 2 | 13% | 35% | 28% | 24% | |
20 nm AuNP | 1.25 | 1.54 × 1010 | 1.94 × 1013 | 55 | 28% | 23% | 26% | 23% |
2.5 | 3.08 × 1010 | 3.88 × 1013 | 27 | 26% | 23% | 29% | 21% | |
5 | 6.16 × 1010 | 7.76 × 1013 | 13 | 25% | 26% | 26% | 23% | |
10 | 1.23 × 1011 | 1.33 × 1014 | 6 | 18% | 32% | 30% | 19% | |
10 nm AgNP | 0.3125 | 5.63 × 1010 | 1.77 × 1013 | 60 | 26% | 24% | 28% | 22% |
0.625 | 1.13 × 1011 | 3.53 × 1013 | 29 | 19% | 34% | 24% | 23% | |
1.25 | 2.25 × 1011 | 7.07 × 1013 | 14 | 20% | 21% | 20% | 24% | |
2.5 | 4.50 × 1011 | 1.41 × 1014 | 7 | 12% | 35% | 29% | 24% | |
Ag citratea | 1.05 | na | na | na | 23% | 27% | 28% | 22% |
2.1 | na | na | na | 22% | 29% | 27% | 21% | |
4.21 | na | na | na | 23% | 28% | 25% | 23% | |
7.5 | na | na | na | 21% | 29% | 28% | 22% |
Ideally, the NP-peptide systems investigated would be such that there are no “free” peptides, i.e. peptide not interacting with the NP surface which could act to “dilute” any effects seen on the secondary structure of the “bound” peptides. Unfortunately, the minimum peptide concentration required to give sufficient CD signal, and issues with high absorbance of the SP-B, TFE and NPs at low wavelengths meant that this was not always possible here. Using a simple geometric model, assuming that the SP-B1–25 molecules are primarily α-helices of 12 Å diameter31,32 which pack “end on” over the surface area of the nanoparticle sphere, the maximum theoretical number of SP-B1–25 molecules that can be packed around each NP are estimated to be 60, 240 and 961 for 5 nm, 10 nm and 20 nm diameter spherical NPs respectively. In reality many factors, such as NP surface charge, size and surface curvature, pH and the presence of other ions can affect packing density and corona formation on metallic NPs33 so these ratios are only intended to give an approximate indication of the level of binding of SP-B1–25 for comparative purposes.
As part of the preparatory work, sample mixing methods to ensure full dissolution of the SP-B1–25, minimise NP agglomeration and to provide stable suspensions were devised. In summary, for TFE samples, NP stock solutions as provided by the manufacturer (20 μg ml−1 for 10 nm AgNPs, 69 μg ml−1, 61 μg ml−1 and 53 μg ml−1 for 5 nm, 10 nm and 20 nm AuNPs respectively) were first diluted in milliQ water to the desired NP concentration and spiked with 0.2 ml of 0.1M PB to give the desired pH. 100% TFE or pre-prepared 20 μg ml−1 SP-B1–25 in TFE stock solution was then added to the NP suspension for buffer control and peptide samples respectively. Samples were then gently mixed with a pipette and rested for 1 hour before use. AuNP samples were found to be stable and resting time not to affect the CD results, but due to the potential for AgNPs to dissolve, resting times were kept consistent. For ionic silver samples, 10 μg ml−1 silver citrate in milliQ was added instead of the NP stock. For DPPC samples, DPPC (1 mg ml−1 in CHCl3) and SP-B1–25 (0.1 mg ml−1 in MeOH) stocks were pre-prepared (DPPC only for buffers), mixed to give a peptide/lipid ratio of 50:
1 and dried down in a fumehood. Approximately 1 hour before use, the powder was resuspended in milliQ and spiked with PB to give the desired pH (7.0) then vortex shaken and warmed at 47 °C in a water bath for 30 minutes. Samples were vortexed again and allowed to cool for at least 10 minutes before the NP stock was added and hand-shaken to give the desired NP concentration. Samples were then rested for 15 minutes before use.
Nanoparticlea | Primary particle diameter (Average![]() ![]() |
Agglomerate surface area equivalent diameter (Average![]() ![]() |
|||
---|---|---|---|---|---|
Manufacturer's data | Without SP-B1–25 | With SP-B1–15 | Without SP-B1–25 | With SP-B1–15 | |
a In TFE unless otherwise stated. | |||||
5 nm Au | 5 ± 15 | 5.4 ± 0.5 | 5.4 ± 0.6 | 19.3 ± 13.7 (N = 47) | 138.9 ± 96.8 (N = 40) |
10 nm Au | 10 ± 2 | 9.4 ± 0.9 | 9.4 ± 0.9 | 34.7 ± 31.1 (N = 83) | 84.8 ± 54.6 (N = 59) |
20 nm Au | 20 ± 15 | 19.9 ± 2.4 | 19.9 ± 3.0 | 72.4 ± 48.3 (N = 55) | 131.5 ± 135.4 (N = 22) |
10 nm Ag | 10 ± 3 | 9.0 ± 3.0 | 8.9 ± 2.8 | 20.0 ± 18.1 (N = 136) | 126.0 ± 139.5 (N = 29) |
10 nm Au (in DPPC) | 10 ± 2 | — | 9.6 ± 0.9 (N = 65) | — | 17.0 ± 11.5 (N = 27) |
The images (Fig. 1) suggest that “looser agglomerates”, with more space observed between particles, were formed with SP-B1–25 for the 5 nm Au and 10 nm Ag NPs than other particles. Although TEM images were only taken for a limited range of concentrations it is assumed that, while the degree of agglomeration could vary with concentration, the overall conclusions regarding agglomeration by SP-B1–25 are relevant for all concentrations.
Dynamic light scattering measurements of hydrodynamic diameter confirmed the formation of NP agglomerates both with and without SP-B1–25, with significantly greater agglomeration with SP-B1–25 compared to without (Table S1,† Fig. S3†). Unfortunately, there was significant variability in the results and the absolute sizes measured are inconsistent with the TEM sizing, suggesting these results should be interpreted with caution. These results perhaps reflect the difficulties DLS is known to have in resolving the size distribution of complex mixtures.
The stability of the dispersions used was explored by undertaking separate measurements of the zeta potential of a limited number of additional dispersions similar to those used for the SRCD measurements and produced using the same protocols. Zeta potential measurements of all sizes of Au and Ag NPs in TFE/PB were negative, with values ranging between – 9 mV, for 10 nm Ag NPs, and –18 to −15 mV for Au NPs (Table S2†). Typically, zeta potentials >25 mV and <−25 mV represent stability, so these dispersions could be considered to display incipient instability. This is consistent with the development of agglomerates seen in the TEM images. The addition of SP-B1–25 shifted the zeta potential towards positive values, indicating an association between the protein and the NPs, but at magnitudes that indicated a reduction in stability, consistent with an increase in agglomerate size, as seen. However, the range of NP concentrations considered did not fully overlap with that used for the SRCD measurements. It is recommended that for future studies zeta potential measurements are made of each experimental dispersion immediately prior to use.
In contrast to the TFE suspensions, agglomerates remained small after addition of SP-B1–25 to the DPPC suspension (Table 2 and Fig. 2). TEM images of the 10 nm AuNPs in DPPC/SP-B1–25 also show evidence of a coating, presumably of DPPC and SP-B, approximately 1 nm thick (Fig. 2), not observed for the NPs in TFE/SP-B. This coating may stabilise the NP suspension and thus limit agglomeration. Dynamic Light Scattering measurements were not made of any DPPC samples.
The pH of the TFE/PB study samples ranged from 5.2–6.4. Whilst this is slightly more acidic than typical quoted values for the alveolar subphase fluid of 6.9,6 it has been hypothesised that there could be localised variability in pH due to the presence of alveolar macrophages.6 However, studies of the effect of pH on the surface tension behaviour of a range of surfactants have indicated that natural lung surfactants are not significantly affected over a pH range from 3–7.5 and that generally a range of 5.0–7.4 is considered optimal for surfactant studies.46
To investigate the changes in the CD spectra further, secondary structure analysis of the SP-B1–25 spectra using the software CDApps42 was carried out. Two fitting algorithms, CONTINLL and CDSSTR, were used with the basis set SMP56 consisting of 43 soluble proteins and 13 membrane proteins.43–45 All fits for both algorithms were within the acceptable standard deviation ranges (<0.07 for CONTINLL and <0.25 for CDSSTR), and the values obtained using both were very consistent. Table 1 gives the α-helix, β-strand, un-ordered and turn components obtained for each NP-peptide complex as the average of the two algorithms. Fig. 4 shows the α-helix component as a function of NP mass concentration and NP primary particle surface area concentration for all the Au and Ag NP samples analysed, and as a function of silver mass concentration for the silver citrate samples, compared to the results for 10 nm AgNPs.
For all NPs investigated, there is a clear trend of decreasing percentage of α-helix with increasing NP mass concentration (Fig. 4B); the extent of which varies between the particle sizes and materials investigated. The AuNPs, for example, show an increasing effect with decreasing particle size. Assuming that the change in secondary structure of the SP-B1–25 is due to a physical interaction with the NP surface, then this is to be expected, as the same mass concentration of different sized particles will have a different surface area available for binding, and indeed, the results for 20 nm and 10 nm AuNPs expressed in terms of primary particle surface area (Fig. 4C) are very similar. However, the results for 5 nm AuNPs and 10 nm AgNPs remain more significant even after surface area has been taken into consideration. Fig. S4† shows that for all the nanoparticles investigated, a decrease in the α-helical component of SP-B1–25's secondary structure corresponded to an increase in amount of β-strand but had no effect on the unordered or turn component.
Fig. 5 shows the results for the SRCD measurements made of SP-B1–25 in DPPC (50:
1 mol
:
mol) with and without 10 nm AuNPs. While the magnitude of the CD signal was smaller, and noise greater for SP-B1–25 dispersed in DPPC, averaging 3 consecutive data sets clearly shows the same characteristic spectral shape as for SP-B1–25 in TFE and consistent with CD spectra for SP-B1–25 in a similar lipid mixture (DPPC
:
POPG, 4
:
1).49 Similarly to the TFE dispersions, with the addition of 10 nm AuNPs, a clear reduction in the magnitude of the spectra minima is observed (see table in Fig. 5), the extent of which increases with NP concentration. The rate of change with increasing concentration is slightly greater for the 208 nm minima compared to the 222 nm minima for both TFE and DPPC, leading to a ‘skew’ in the CD spectra as the nanoparticle concentration increases, and a decrease in the ratio of ellipticities at 208 nm and 222 nm, a parameter sensitive to changes in the CD spectrums shape.47
As secondary structure analysis using CDApps was not possible for the DPPC samples, secondary structure was estimated using the BeStSel web application.50,51 While results suggest a similar effect on the secondary structure of the SP-B1–25 in DPPC as for TFE with the addition of 10 nm AuNPs, firm conclusions cannot be drawn without further work. See ESI (Fig. S5†) for the results of the BeStSel analysis and further discussion.
Comparing the results for AgNPs and silver citrate for similar silver concentrations (Fig. 3 and 4) indicates that the ionic silver has a much less significant impact on the protein structure than the NPs, highlighting the effect of the particle surface on the protein conformation.
For both NP types and all sizes investigated we observed an increase in conformational change of SP-B1–25 with greater β-strand content at the expense of α-helix with increased NP concentration expressed as either mass, particle number concentration (not shown) or primary particle surface area. This has been reported in other studies, for example, Capomaccio et al. observed a decrease in the α-helicity of HSA (human serum albumin) produced by exposure to 14 nm AuNPs that increased with concentration.52 Such findings are consistent with a primary hypothesis of surface interactions leading to conformation changes. The similarity between these results for the 20 nm and 10 nm AuNPs expressed in terms of primary particle surface area (Fig. 4) supports the importance of this parameter.
The effects of 5 nm AuNPs, however, remain more significant than for the larger AuNPs even when primary particle surface area is taken into account. There are a number of potential explanations for this difference. The estimates of bound and free proteins were undertaken using the same simplistic assumptions for each particle size (including complete monolayer coverage). It is possible though that binding is proportionally greater for the smaller particles (the qualitatively looser agglomerates for the 5 nm AuNPs (Fig. 1) may suggest a greater binding potential, although this would clearly require further investigation). This would be consistent with the findings of Hill et al. 200953 on the loading of oligonucleotides on AuNPs (range 10 nm – 200 nm), which found that loading (per unit surface area) decreased approximately exponentially with increasing radius until around 60 nm after which values remained broadly constant and comparable to values for planar surfaces. They hypothesised that this was due to increased deflection between strands and decreased steric interaction. Zhang et al.54 also found that smaller AgNPs (16 nm) produced a greater reduction in α-helicity of HSA than larger (26 and 40 nm). Other studies have, however, indicated the opposite effect with larger particles resulting in proportionally greater protein binding55,56 and/or causing more significant effects on protein secondary structure57,58 than smaller.
It is clear that the degree of protein binding and conformational changes depend in a complex manner on the physiochemical characteristics of the NPs and the characteristics of the protein and biological environment (see previous reviews27,33,59). For example, Qu et al. found differences in binding and conformation changes of HSA with Quantum Dots with different ligands,60 and modelling undertaken by Khan et al.61 indicated that the orientation of proteins on NPs varied with particle size, with the orientation switching from one conformation to another at 12 nm for ubiquitin and 3–5 nm for insulin and haemoglobin. For human serum albumin, four different orientations were identified relating to the following particle sizes: 1–3, 4–10, 11–20 and >20 nm. Differences in orientation would be expected to impact on corona formation including the density of packing.
As well as the difference between 5 nm and larger AuNPs, the degree of conformational change induced by the 10 nm AgNPs was markedly greater than that for AuNPs of the same size and surface area concentration. Silver is intrinsically more soluble than gold so one possible hypothesis for the difference is that silver ions released from the AgNPs are affecting the protein structure. However, our results comparing AgNPs with silver ions of equivalent mass (Fig. 3 and 4) indicate minimal effects on the protein secondary structure of the silver ions. The difference between the results for 10 nm Au and 10 nm Ag NPs may be a result of differences in protein binding arising from the presence of citrate in the Ag but not the Au dispersion, and this could usefully be investigated further. Other studies have indicated that the type of nanoparticle can have a significant impact on protein binding, e.g. more plasma protein bound to silica than polystyrene NPs of the same size at low plasma protein concentrations.62 Lai et al.,63 examined the protein corona formed from human plasma on 20 nm Au and Ag NPs with different surface modifications and found differences in the characteristics of the corona (size, constituent proteins) related both to the core material and surface charge.
TFE is clearly not physiologically relevant, and some experts advise against the use of organic solvents, including TFE, in CD spectroscopy due to the potential for effects of solvents on protein structure,29 however, TFE is widely used in CD and a study considering the structure of porcine extracted SP-B in a range of TFE/water mixtures found that SP-B maintained a very stable conformation in mixtures containing up to 70% TFE.47 The same research group also found that the conformation of SP-B in TFE (70%) and DPPC vesicles was very similar.64 However, experiments with more realistic models reflecting the range of lipids and proteins present in lung surfactant are necessary to confirm the findings as relevant to complete surfactant as the interactions between NP and SP-B1–25 may be affected by the presence of other biomolecules.
TFE may also contribute to the NP agglomeration observed in suspensions both with and without SP-B1–25 (Fig. 1, Table 2 and Table S1, Fig. S3†). In contrast, only minimal agglomeration was observed for DPPC suspensions. NP agglomeration, prior to the addition of SP-B1–25, leads to uncertainty in the surface area available for binding. Depending on the strength of the adhesive forces holding the NPs together, a smaller surface area could be available for binding with SP-B1–25. While the absolute surface area available for binding may be uncertain, and therefore the degree of “dilution” of any conformational changes observed caused by any unbound SP-B1–25 in the suspension, it does not negate the fact that conformational changes were observed due to the interaction of Au and Ag NPs with SP-B1–25. To limit this uncertainty though, in any future work, using DPPC to suspend the SP-B1–25 would not only be more realistic, but also limit agglomeration, however, this would require improvements in signal strength.
Comparison studies in vitro have indicated that SP-B1–25 functions similarly to complete SP-B (e.g. Lipp et al.65) and in vivo studies in deficient animal models have confirmed improvements in lung function using this analogue.66,67 Although it is not as effective as the dimeric form and cannot replicate the full functions of native SP-B as effectively as some more complete analogues.28,68 Additional studies would be needed to confirm the relevance of these findings to the complete protein, which may for example, exhibit different binding patterns.
To probe any conformational change in SP-B1–25 when adsorbed on the NP surface, ideally the NP-peptide system would be such that there are no “free” peptides. This requires a very low concentration of the mixture. Measurement of conformational changes of proteins by CD spectroscopy in sub-micromolar concentrations can only be achieved using a long pathlength cell. SRCD measurement at the Diamond Light Source B23 beamline, with its highly collimated beam, allows the measurement of very low volume samples of micromolar and sub-micromolar concentrations (∼300–600 μL) using a long pathlength, small aperture cell. A previous study using protein concentrations similar to those used here indicated that such measurements could not be undertaken using bench top CD instruments, due to the large highly divergent beam.69 Unfortunately, in this study the minimum peptide concentration required to give sufficient signal, and issues with the high absorbance of the SP-B1–25, TFE and NPs at low wavelengths meant that “free” peptide was probably present in all samples (estimates using simple geometric consideration, Table 1). Consideration should be given in future studies to improving the ratio of free to bound peptide, perhaps using experimental protocols to remove the unbound protein from the suspension and/or techniques to quantify the bound peptide, and potentially the use of NP and protein concentrations which are more environmentally and physiologically relevant.
On the basis of previous studies demonstrating the ability of NPs to modify protein secondary structure (e.g. as reviewed by Park27), we posited an alternative hypothesis, i.e. NPs modify the secondary structure of SPs, which affects their behaviour (e.g. inactivates) within pulmonary surfactant and consequently adversely affects surfactant film function. In this study we have explored this hypothesis using two types of NPs and demonstrated that both Au and Ag NPs can modify the structure, and therefore have implications for the proper functioning of, an SP-B analogue, SP-B1–25. Whilst consideration of the structure of the complete SP-B molecule suggests that this would also be similarly affected, this remains to be confirmed and may differ in degree. Additional studies using other NPs are also required to test whether these findings are broadly applicable or only valid for specific types of NPs. Whether changes to the secondary structure of SP-B impacts on model pulmonary surfactant film behaviour would also require investigation to fully test this hypothesis.
Further studies of surfactant film behaviour could then usefully be undertaken to investigate whether for specific NPs either ‘sequestration’ or ‘modification’ act alone or in combination to produce any effects seen. These should consider the NP biomolecular corona. It is known that these can be dynamic, undergoing exchange with the surrounding medium (i.e. it is possible that adsorbed and modified SP-B could be released and reincorporated in the surfactant layer). Results of a recent review suggest that the position regarding the reversibility, or otherwise, of adsorption of a specific protein on NPs is unclear, with findings varying with many factors including, particle type and size, the characteristics of the medium (e.g. number and type of proteins) and experimental factors, such as time and concentrations.70 Such studies should reflect relevant physiological timescales by considering the metabolism of SP-B. The main components of surfactant are produced in alveolar type II cells. The lipids and SP-B and SP-C are secreted together in lamellar bodies into the hypophase, these ‘unravel’ to form tubular myelin and large lipid arrays which adsorb to the interface to form the surface film. After ‘use’ the surfactant is partly recycled by type II cells (e.g. 50% recycling DPPC in rabbits) with the remainder catabolised by macrophages or type II cells with biological half-times of phosphatidylcholine species ranging from 8 to 12 h in mice, rats and rabbits, with shorter biological turnover times because of recycling.71 Similar recycling of SP-B has been demonstrated in animal models, although different half-times have been seen: 28 h in mice (DPPC ∼11 h)72 and 7 h (DPPC ∼11 h) in mature rabbits.73 These are broadly consistent with values for newborn infants, 21 h (8–35 h).74
It is accepted that the use of surfactant film model systems are very useful for identifying the potential impact of particulate matter, however, they cannot reflect all physiological aspects of the system.10 To discover whether any modifications seen in vitro to surfactant model function by NPs translate to physiological effects (i.e. negative impact on breathing) would require the use of in vivo models. It is important that such studies use realistic NP exposure levels.
Further investigation may indicate that effects on surfactant protein structure could be one form of molecular initiating event (MIE) leading to decreased lung function (adverse outcome (AO)) and therefore potentially contribute to the future development and expansion of the Adverse Outcome Pathway (AOP) developed by Da Silva et al. (2021) – lung surfactant function inhibition (MIE) leading to decreased lung function (AO) (https://www.aopwiki.org/aops/302 and https://aopkb.oecd.org).75
Footnote |
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d2nr06107d |
This journal is © The Royal Society of Chemistry 2023 |